Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Challenges in IBD Research: Environmental Triggers.

Ho SM, Lewis JD, Mayer EA, Plevy SE, Chuang E, Rappaport SM, Croitoru K, Korzenik JR, Krischer J, Hyams JS, Judson R, Kellis M, Jerrett M, Miller GW, Grant ML, Shtraizent N, Honig G, Hurtado-Lorenzo A, Wu GD.

Inflamm Bowel Dis. 2019 May 16;25(Supplement_2):S13-S23. doi: 10.1093/ibd/izz076. Erratum in: Inflamm Bowel Dis. 2019 Nov 14;25(12):e171.

PMID:
31095702
2.

Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.

Olden KW, Chey WD, Shringarpure R, Paul Nicandro J, Chuang E, Earnest DL.

Curr Med Res Opin. 2019 Mar;35(3):461-472. doi: 10.1080/03007995.2018.1533456. Epub 2018 Nov 22.

PMID:
30293448
3.

Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint.

Lacy BE, Nicandro JP, Chuang E, Earnest DL.

Therap Adv Gastroenterol. 2018 May 8;11:1756284818771674. doi: 10.1177/1756284818771674. eCollection 2018.

4.

Molecular Pathophysiology of Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases.

Lee JY, Wasinger VC, Yau YY, Chuang E, Yajnik V, Leong RW.

Proteomes. 2018 Mar 31;6(2). pii: E17. doi: 10.3390/proteomes6020017. Review.

5.

Food regulations: low FODMAP labeling and communication goals.

Méance S, Giordano J, Chuang E, Schneider H.

J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:62-63. doi: 10.1111/jgh.13699. Review.

PMID:
28244659
6.

Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.

Stein R, Lee D, Leonard MB, Thayu M, Denson LA, Chuang E, Herskovitz R, Kerbowski T, Baldassano RN.

Inflamm Bowel Dis. 2016 Jun;22(6):1370-7. doi: 10.1097/MIB.0000000000000769.

PMID:
27057683
7.

Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.

Zitomersky NL, Atkinson BJ, Fournier K, Mitchell PD, Stern JB, Butler MC, Ashworth L, Hauenstein S, Heiner L, Chuang E, Singh S, Bousvaros A.

Inflamm Bowel Dis. 2015 Feb;21(2):307-14. doi: 10.1097/MIB.0000000000000284.

8.

Systems biology approaches for inflammatory bowel disease: emphasis on gut microbial metabolism.

Moco S, Candela M, Chuang E, Draper C, Cominetti O, Montoliu I, Barron D, Kussmann M, Brigidi P, Gionchetti P, Martin FP.

Inflamm Bowel Dis. 2014 Nov;20(11):2104-14. doi: 10.1097/MIB.0000000000000116. Review.

PMID:
25029616
9.

A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.

Tong K, Nicandro JP, Shringarpure R, Chuang E, Chang L.

Therap Adv Gastroenterol. 2013 Sep;6(5):344-57. doi: 10.1177/1756283X13491798.

10.

Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.

Plevy S, Silverberg MS, Lockton S, Stockfisch T, Croner L, Stachelski J, Brown M, Triggs C, Chuang E, Princen F, Singh S.

Inflamm Bowel Dis. 2013 May;19(6):1139-48. doi: 10.1097/MIB.0b013e318280b19e.

11.

Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.

Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Salbato J, Reddy R, McCowen K, Shah S, Lockton S, Chuang E, Singh S.

J Pharm Biomed Anal. 2013 May 5;78-79:39-44. doi: 10.1016/j.jpba.2013.01.031. Epub 2013 Feb 1.

12.

Evaluation of treatment continuation with alosetron by IBS-D severity criteria.

Nicandro JP, Shin P, Chuang E.

Curr Med Res Opin. 2012 Mar;28(3):449-56. doi: 10.1185/03007995.2011.653435. Epub 2012 Feb 7.

PMID:
22313141
13.

Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.

Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F, Carroll S, Brown M, Stachelski J, Chuang E, Landers CJ, Stempak JM, Singh S, Silverberg MS.

Inflamm Bowel Dis. 2011 Dec;17(12):2488-96. doi: 10.1002/ibd.21661. Epub 2011 Mar 9.

14.

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group.

N Engl J Med. 2010 Jul 15;363(3):245-56. doi: 10.1056/NEJMoa0909809.

15.

Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.

Al-Shamma HA, Anderson C, Chuang E, Luthringer R, Grottick AJ, Hauser E, Morgan M, Shanahan W, Teegarden BR, Thomsen WJ, Behan D.

J Pharmacol Exp Ther. 2010 Jan;332(1):281-90. doi: 10.1124/jpet.109.160994. Epub 2009 Oct 19.

PMID:
19841476
16.

APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia.

Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, Prosser W, Shanahan W, Sanchez M, Chuang E, Roth T.

Sleep. 2008 Dec;31(12):1663-71.

17.
18.

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM.

Circulation. 2006 Oct 17;114(16):1729-35. Epub 2006 Oct 9.

PMID:
17030687
19.

Primary sclerosing cholangitis in children: a histologic follow-up study.

Batres LA, Russo P, Mathews M, Piccoli DA, Chuang E, Ruchelli E.

Pediatr Dev Pathol. 2005 Sep-Oct;8(5):568-76. Epub 2005 Oct 7.

PMID:
16220233
20.

Biomedicines to reduce inflammation but not viral load in chronic HCV--what's the sense?

Chuang E, Del Vecchio A, Smolinski S, Song XY, Sarisky RT.

Trends Biotechnol. 2004 Oct;22(10):517-23. Review.

PMID:
15450745

Supplemental Content

Loading ...
Support Center